Pearl Steinzor

Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital in San Diego, shared the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD), for future clinical practice.

The risk for incident autoimmune inflammatory rheumatic disease (AIRD) was greater among patients with a history of COVID-19 infection.

Will Shapiro, vice president of data science at Flatiron Health, discusses how the practice is using large language models (LLMs) to increase efficiency, while ensuring there are frameworks set for safety and quality.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, addresses challenges in identifying patients with generalized pustular psoriasis (GPP) and how artificial intelligence (AI) can help alleviate these concerns.

The approval of benralizumab (Fasenra) is supported by evidence from the phase 3 TATE study.

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, shares the importance of incorporating a culture of well-being within oncology practices.

Public health policies should address risk factors among individuals who are most at risk of asthma, researchers suggest.

Patients with moderate to severe psoriasis and a history of cancer have improved symptoms and a favorable safety profile with guselkumab treatment, according to a new study.

Robert Sidbury, MD, MPH, FAAD, division head of dermatology at Seattle Children's Hospital and professor of pediatrics at the University of Washington School of Medicine, discusses implementing value-based care initiatives in a pediatric dermatology practice.

Accelerated biological aging may be behind why some types of cancer are on the rise in young adults, researchers find.

Lawrence Eichenfield, MD, of Rady Children's Hospital - San Diego, discusses the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD).

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, shares insights on how peer support groups can help manage psychological and emotional distress amid a national drug shortage.

Will Shapiro, vice president of data science at Flatiron Health, explains the different ethical challenges associated with various forms of artificial intelligence models used in oncology care.

President Joe Biden and Senator Bernie Sanders continue their push to cut the cost of asthma inhalers and prescription drugs in the US.

Joseph Zabinski, PhD, MEM, vice president, head of commercial strategy and AI, OM1, discusses ways that AI is being integrated into personalized medicine for patients with generalized pustular psoriasis (GPP).

Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health, discusses the impact of peer support groups within a health care organization and its patients.

Patients with acute asthma exacerbations who do not suppress eosinophils after a course of oral corticosteroids (OCS) may have slower clinical recovery, according to one study.

Roflumilast cream may be suitable for chronic treatment, including the face and intertriginous areas, according to one study.

Monica Li, MD, medical and cosmetic dermatologist, listed microneedling considerations and precautions so that providers can safely implement the procedure.

Jonathan Silverberg, MD, PhD, MPH, FAAD, of George Washington University School of Medicine and Health Sciences, discusses atopic dermatitis (AD) diagnosis and treatment differences in children vs adults.

Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, described monitoring protocols for clinicians when using oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

Despite the positive week 48 results when used to treat moderate to severe hidradenitis suppurativa (HS), Jeff Stark, MD, of Union Chimique Belge, noted that bimekizumab is still considered an investigational therapy for HS treatment as it has not yet received an FDA approval.

Will Shapiro, vice president of data science at Flatiron Health, discusses opportunities to implement artificial intelligence in cancer care.

Posters presented at the American Academy of Dermatology Annual Meeting identified significant undertreatment of psoriasis and significant gaps in biologic medication treatment.

Ravulizumab-cwvz (Ultomiris) received a label expansion by the FDA for the treatment of adult neuromyelitis optica spectrum disorder in patients with anti–aquaporin-4 antibodies after trials results showed it could prevent relapses.

Explainability, consent, and responsibility are noted as challenges that may hinder implementation of artificial intelligence (AI) in cancer care, according to a new study.

Jeff Stark, MD, vice president and head of immunology, UCB, discusses findings on improved pain management in patients with moderate to severe hidradenitis suppurativa (HS).

Dupilumab significantly reduced the risk of exacerbations compared with placebo in children with moderate to severe asthma, regardless of exacerbation history.

Raj Chovatiya, MD, PhD, associate professor at the Rosalind Franklin University of Medicine and Science, provided current clinical evidence supporting the use of oral Janus kinase (JAK) inhibitors to treat patients with atopic dermatitis (AD).

Areas with high proportions of Black and Latinx residents face high rates of asthma-related emergency department visits, according to one study.